Irene Lener, OTR in Charlestown, RI - Occupational Therapist

Irene Lener, OTR is a Occupational Therapist based in Charlestown, Rhode Island. Irene Lener is licensed to practice in Rhode Island (license number 01540) and her current practice location is 442 Narrow Lane, Charlestown, Rhode Island. She can be reached at her office (for appointments etc.) via phone at (401) 364-3860.

NPI number for Irene Lener is 1689122004 and her current mailing address is Po Box 359, 442 Narrow Lane, Charlestown, Rhode Island. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1689122004.

Contact Information

	Irene Lener, OTR
	442 Narrow Lane, Charlestown, RI 02813-0359
	(401) 364-3860
	Not Available

Healthcare Provider's Profile

Full Name	Irene Lener
Gender	Female
Speciality	Occupational Therapist
Location	442 Narrow Lane, Charlestown, Rhode Island
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1689122004
Provider Enumeration Date: 09/14/2016
Last Update Date: 09/14/2016

Medical Identifiers

Medical identifiers for Irene Lener such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1689122004	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225X00000X	Occupational Therapist	01540 (Rhode Island)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Irene Lener is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Irene Lener, OTR Po Box 359, 442 Narrow Lane, Charlestown, RI 02813-0359 Ph: (401) 364-3860	Irene Lener, OTR 442 Narrow Lane, Charlestown, RI 02813-0359 Ph: (401) 364-3860

News Archive

First pelvic reconstruction surgery in cancer patient performed at Ohio State's Medical Center

In a rare and medically remarkable operation, a multi-disciplinary team of surgeons at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute removed the left leg, hip and pelvis of a cancer patient, and used the healthy, living bones from his amputated leg to completely rebuild the connection between his spine and remaining right pelvis to support a high-tech prosthetic leg.

Study identifies venous thromboembolism risk factors after THR surgery

Risk factors for venous thromboembolism after total hip replacement (THR) surgery were identified in a new study published in the September 2010 issue of The Journal of Bone and Joint Surgery (JBJS). While the rate of thromboembolism has been significantly reduced through medication, understanding the risk factors could further reduce the likelihood of patients developing this potentially fatal complication.

Long term antiretroviral therapy may restore CD4 cell counts in HIV positive patients

HIV positive patients who take combination antiretroviral therapy (cART) to combat HIV infection could see the numbers of CD4 cells in their immune system rise to concentrations found in HIV negative individuals, if they remain on the therapy for long enough and their HIV viral load load is suppressed to below 50 copies per ml.

Novel method predicts risk of sudden cardiac death in hemodialysis patients

A new test has been developed to predict sudden cardiac death in hemodialysis patients in whom such forecasts were previously impossible. The novel method was presented at ICNC 12 by Dr Akiyoshi Hashimoto, a cardiologist at Sapporo Medical University in Japan. The test uses a combination of nuclear medicine, C-reactive protein and electrocardiogram (ECG).

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Kolltan Pharmaceuticals, Inc. today announced the presentation of data from a preclinical study evaluating KTN0158 in dogs with spontaneous mast cell tumors. KTN0158 is a proprietary, humanized anti-KIT IgG1 monoclonal antibody drug candidate being developed as a potential therapy for cancer and mast cell-related diseases.

Irene Lener, OTR - Occupational Therapist in Charlestown, RI